News & Updates

Prolonged-release pirfenidone shows therapeutic potential in post–COVID-19 pulmonary fibrosis

22 Jul 2023

A 3-month course of prolonged-release pirfenidone formulation appears to be safe and efficacious in the treatment of patients with postacute sequelae of COVID-19 (PASC)-pulmonary fibrosis, as shown in a study.

Prolonged-release pirfenidone shows therapeutic potential in post–COVID-19 pulmonary fibrosis

22 Jul 2023

Type 2 diabetes: Semaglutide pill works just as well as injectable

22 Jul 2023 by

Treatment with either oral or subcutaneous semaglutide yields favourable outcomes for patients with type 2 diabetes (T2D), according to real-world data.

Type 2 diabetes: Semaglutide pill works just as well as injectable

22 Jul 2023

Low-dose vaginal misoprostol best approach for outpatient cervical ripening

22 Jul 2023

For outpatient cervical ripening and labour induction, low-dose vaginal misoprostol has the most favourable risk-benefit profile, reducing the interval to delivery, according to the results of a systematic review and network meta-analysis.

Low-dose vaginal misoprostol best approach for outpatient cervical ripening

22 Jul 2023

Semaglutide, insulin degludec sustain glycaemic control in patients with T2D

22 Jul 2023 by

Treatment with once-weekly subcutaneous semaglutide and once-daily insulin degludec sustained an HbA_1c level of ≤7.5 percent in individuals with adequately controlled type 2 diabetes (T2D) who were on multiple daily injections of insulin (MDI) regimen, according to the TRANSITION-T2D study presented at ADA 2023.

Semaglutide, insulin degludec sustain glycaemic control in patients with T2D

22 Jul 2023

Add-on danicopan improves outcomes in patients with PNH, cs-EVH

21 Jul 2023 by

In the ongoing pivotal phase III ALPHA trial, add-on danicopan, an investigational first-in-class oral inhibitor of Factor D, appears better than placebo in increasing haemoglobin levels and maintaining disease control in individuals with paroxysmal nocturnal haemoglobinuria (PNH) and clinically significant extravascular haemolysis (cs-EVH) who were already on C5 inhibitors (ravulizumab or eculizumab).

Add-on danicopan improves outcomes in patients with PNH, cs-EVH

21 Jul 2023

Conjugated estrogens/bazedoxifene use tied to higher rates of endometrial cancer, hyperplasia

21 Jul 2023

In the first years of use, conjugated estrogens/bazedoxifene (CE/BZA) appears to be associated with slightly higher rates of endometrial cancer and endometrial hyperplasia compared with estrogen/progestin (EP) combination hormone therapy, according to a study.

Conjugated estrogens/bazedoxifene use tied to higher rates of endometrial cancer, hyperplasia

21 Jul 2023

Mycophenolate mofetil prompts remission better than azathioprine in autoimmune hepatitis

20 Jul 2023 by

Among patients with treatment-naïve autoimmune hepatitis, more of those who receive mycophenolate mofetil achieve remission than those who receive azathioprine, as shown in the results of the CAMARO trial.

Mycophenolate mofetil prompts remission better than azathioprine in autoimmune hepatitis

20 Jul 2023

Simvastatin plus beta blocker improves survival of cirrhotic patients with variceal bleeding

20 Jul 2023 by

The addition of simvastatin to a nonselective beta blocker results in better survival among cirrhotic patients with variceal bleeding, reports a study presented at EASL 2023.

Simvastatin plus beta blocker improves survival of cirrhotic patients with variceal bleeding

20 Jul 2023

Tirzepatide bests placebo, other glucose-lowering drugs at keeping lipid levels, waistline in check

19 Jul 2023

Treatment with tirzepatide is associated with better lipid profile and waist circumference outcomes compared with placebo and other glucose-lowering drugs, according to a study.

Tirzepatide bests placebo, other glucose-lowering drugs at keeping lipid levels, waistline in check

19 Jul 2023

Resmetirom delivers improved outcomes for NASH patients with fibrosis

19 Jul 2023 by

The THR-β selective agonist resmetirom helps resolve nonalcoholic steatohepatitis (NASH) and reduce fibrosis, with the drug being safe and well-tolerated, according to data from the large phase III pivotal MAESTRO-NASH trial presented at EASL 2023.

Resmetirom delivers improved outcomes for NASH patients with fibrosis

19 Jul 2023

News & Updates

Filter by Specialty:

Specialty:

Prolonged-release pirfenidone shows therapeutic potential in post–COVID-19 pulmonary fibrosis

Prolonged-release pirfenidone shows therapeutic potential in post–COVID-19 pulmonary fibrosis

Type 2 diabetes: Semaglutide pill works just as well as injectable

Type 2 diabetes: Semaglutide pill works just as well as injectable

Low-dose vaginal misoprostol best approach for outpatient cervical ripening

Low-dose vaginal misoprostol best approach for outpatient cervical ripening

Semaglutide, insulin degludec sustain glycaemic control in patients with T2D

Semaglutide, insulin degludec sustain glycaemic control in patients with T2D

Add-on danicopan improves outcomes in patients with PNH, cs-EVH

Add-on danicopan improves outcomes in patients with PNH, cs-EVH

Conjugated estrogens/bazedoxifene use tied to higher rates of endometrial cancer, hyperplasia

Conjugated estrogens/bazedoxifene use tied to higher rates of endometrial cancer, hyperplasia

Mycophenolate mofetil prompts remission better than azathioprine in autoimmune hepatitis

Mycophenolate mofetil prompts remission better than azathioprine in autoimmune hepatitis

Simvastatin plus beta blocker improves survival of cirrhotic patients with variceal bleeding

Simvastatin plus beta blocker improves survival of cirrhotic patients with variceal bleeding

Tirzepatide bests placebo, other glucose-lowering drugs at keeping lipid levels, waistline in check

Tirzepatide bests placebo, other glucose-lowering drugs at keeping lipid levels, waistline in check

Resmetirom delivers improved outcomes for NASH patients with fibrosis

Resmetirom delivers improved outcomes for NASH patients with fibrosis